## Annamaria Biroccio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8711925/publications.pdf

Version: 2024-02-01

91712 76196 5,415 102 40 69 citations h-index g-index papers 105 105 105 7233 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. Journal of Clinical Oncology, 2003, 21, 927-931.	0.8	274
2	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. Journal of Clinical Investigation, $2007, 117, 3236-3247$ .	3.9	212
3	Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds. Molecular Cell, 2016, 61, 449-460.	4.5	185
4	c-Myc Phosphorylation Is Required for Cellular Response to Oxidative Stress. Molecular Cell, 2006, 21, 509-519.	4.5	175
5	$\hat{l}^2$ -Arrestin links endothelin A receptor to $\hat{l}^2$ -catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2806-2811.	3.3	159
6	TRF2 and Apollo Cooperate with Topoisomerase $2\hat{l}_{\pm}$ to Protect Human Telomeres from Replicative Damage. Cell, 2010, 142, 230-242.	13.5	155
7	Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Research, 2009, 37, 5353-5364.	6.5	152
8	BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications, 2019, 10, 3143.	5.8	141
9	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of Experimental and Clinical Cancer Research, 2018, 37, 57.	3.5	140
10	Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. Molecular Pharmacology, 2004, 66, 1138-1146.	1.0	134
11	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	1.0	132
12	Bclâ $\bf e 2$ overexpression enhances the metastatic potential of a human breast cancer line. FASEB Journal, 1997, 11, 947-953.	0.2	126
13	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death and Differentiation, 2005, 12, 1429-1438.	5.0	124
14	c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer. American Journal of Pathology, 2001, 158, 1289-1299.	1.9	122
15	Bclâ€2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIFâ€1 mediated transcriptional activity. FASEB Journal, 2002, 16, 1453-1455.	0.2	117
16	Bclâ€2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and <i>in vivo</i> angiogenesis in a breast carcinoma line. FASEB Journal, 2000, 14, 652-660.	0.2	115
17	Patient-derived xenografts: a relevant preclinical model for drug development. Journal of Experimental and Clinical Cancer Research, 2016, 35, 189.	3.5	109
18	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene, 2010, 29, 6280-6293.	2.6	103

#	Article	IF	Citations
19	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nature Cell Biology, 2013, 15, 818-828.	4.6	99
20	bcl-2 over-expression enhances NF-?B activity and induces mmp-9 transcription in human MCF7ADR breast-cancer cells., 2000, 86, 188-196.		89
21	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International Journal of Cancer, 2002, 98, 463-469.	2.3	87
22	C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells. Molecular Pharmacology, 2001, 60, 174-182.	1.0	82
23	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	3.2	82
24	The future of antisense therapy: combination with anticancer treatments. Oncogene, 2003, 22, 6579-6588.	2.6	79
25	$\hat{l}^2$ -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced $\hat{l}^2$ -catenin signaling. Oncogene, 2013, 32, 5066-5077.	2.6	79
26	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	2.7	75
27	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. International Journal of Cancer, 2003, 104, 243-250.	2.3	72
28	TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. European Journal of Cancer, 2006, 42, 1881-1888.	1.3	62
29	Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Therapy, 2001, 8, 459-468.	2.2	60
30	<scp>BRCA</scp> 1 and <scp>BRCA</scp> 2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Molecular Medicine, 2017, 9, 1398-1414.	3.3	57
31	Shooting for Selective Druglike G-Quadruplex Binders: Evidence for Telomeric DNA Damage and Tumor Cell Death. Journal of Medicinal Chemistry, 2012, 55, 9785-9792.	2.9	53
32	N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage. Journal of Medicinal Chemistry, 2011, 54, 1140-1156.	2.9	51
33	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <scp>TRF</scp> 2. EMBO Journal, 2019, 38, .	3.5	49
34	Exploring the Chemical Space of G-Quadruplex Binders: Discovery of a Novel Chemotype Targeting the Human Telomeric Sequence. Journal of Medicinal Chemistry, 2013, 56, 9646-9654.	2.9	48
35	Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells. Journal of Biological Chemistry, 2002, 277, 43763-43770.	1.6	47
36	Che-1 Arrests Human Colon Carcinoma Cell Proliferation by Displacing HDAC1 from the p21 Promoter. Journal of Biological Chemistry, 2003, 278, 36496-36504.	1.6	46

#	Article	IF	CITATIONS
37	Looking for Efficient Gâ€Quadruplex Ligands: Evidence for Selective Stabilizing Properties and Telomere Damage by Drug‣ike Molecules. ChemMedChem, 2015, 10, 640-649.	1.6	46
38	Glutathione Depletion Induced by c-Myc Downregulation Triggers Apoptosis on Treatment with Alkylating Agents. Neoplasia, 2004, 6, 195-206.	2.3	45
39	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	6.5	45
40	SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage. Nucleic Acids Research, 2017, 45, 1820-1834.	6.5	43
41	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. Molecular Pharmacology, 2003, 63, 192-202.	1.0	42
42	Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance. Nucleic Acids Research, 2016, 44, 1579-1590.	6.5	40
43	Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. Journal of Cellular Physiology, 2005, 204, 463-469.	2.0	38
44	Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein. Nucleic Acids Research, 2019, 47, 9950-9966.	6.5	38
45	AKTIP/Ft1, a New Shelterin-Interacting Factor Required for Telomere Maintenance. PLoS Genetics, 2015, 11, e1005167.	1.5	38
46	Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1341-1352.	1.1	35
47	Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis. Journal of Biological Chemistry, 2003, 278, 35693-35701.	1.6	34
48	Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocrine-Related Cancer, 2004, 11, 407-421.	1.6	34
49	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. Nucleic Acids Research, 2019, 47, 3365-3382.	6.5	34
50	DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents. Clinical Cancer Research, 2011, 17, 2227-2236.	3.2	33
51	Aromatic Core Extension in the Series of Nâ€Cyclic Bayâ€Substituted Perylene Gâ€Quadruplex Ligands: Increased Telomere Damage, Antitumor Activity, and Strong Selectivity for Neoplastic over Healthy Cells. ChemMedChem, 2012, 7, 2144-2154.	1.6	33
52	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. European Journal of Cancer, 2002, 38, 2455-2462.	1.3	32
53	Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. Journal of Experimental and Clinical Cancer Research, 2014, 33, 81.	3.5	32
54	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Therapy, 1999, 6, 1064-1072.	2.3	31

#	Article	IF	CITATIONS
55	bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cells., 1999, 82, 125-130.		31
56	Identification of novel interactors of human telomeric G-quadruplex DNA. Chemical Communications, 2015, 51, 2964-2967.	2.2	31
57	Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. Journal of Experimental and Clinical Cancer Research, 2017, 36, 189.	3.5	30
58	Emerging roles of telomeric chromatin alterations in cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 21.	3.5	30
59	Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene, 2002, 21, 3011-3019.	2.6	29
60	The telomeric protein AKTIP interacts with A- and B-type lamins and is involved in regulation of cellular senescence. Open Biology, 2016, 6, 160103.	1.5	29
61	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. Molecular Pharmacology, 2003, 63, 632-638.	1.0	27
62	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. Molecular Cancer Therapeutics, 2015, 14, 2541-2551.	1.9	27
63	Smad-Interacting Protein-1 and MicroRNA 200 Family Define a Nitric Oxide–Dependent Molecular Circuitry Involved in Embryonic Stem Cell Mesendoderm Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 898-907.	1.1	26
64	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	3.3	26
65	In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. International Journal of Cancer, 2004, 110, 767-774.	2.3	25
66	A bimodal fluorescent and photocytotoxic naphthalene diimide for theranostic applications. Organic and Biomolecular Chemistry, 2016, 14, 7238-7249.	1.5	25
67	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	1.8	24
68	Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex. Frontiers in Chemistry, 2014, 2, 54.	1.8	24
69	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. Journal of Medicinal Chemistry, 2017, 60, 3626-3635.	2.9	24
70	Tailoring a lead-like compound targeting multiple G-quadruplex structures. European Journal of Medicinal Chemistry, 2019, 163, 295-306.	2.6	24
71	Shading the TRF2 Recruiting Function: A New Horizon in Drug Development. Journal of the American Chemical Society, 2014, 136, 16708-16711.	6.6	23
72	On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 68.	3.5	22

#	Article	IF	CITATIONS
73	Therapeutic integration of câ€myc and bclâ€2 antisense molecules with docetaxel in a preclinical model of hormoneâ€refractory prostate cancer. Prostate, 2007, 67, 1475-1485.	1.2	21
74	Inhibition of PARP activity by PJâ€34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. Journal of Cellular Physiology, 2010, 222, 401-410.	2.0	21
75	Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. Biochimie, 2016, 125, 223-231.	1.3	21
76	Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer, 2010, 70, 271-279.	0.9	20
77	Trifunctionalized Naphthalene Diimides and Dimeric Analogues as G-Quadruplex-Targeting Anticancer Agents Selected by Affinity Chromatography. International Journal of Molecular Sciences, 2020, 21, 1964.	1.8	20
78	EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1362-1370.	1.1	17
79	Methods of studying telomere damage induced by quadruplex-ligand complexes. Methods, 2012, 57, 93-99.	1.9	16
80	Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 866-871.	1.5	15
81	A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds. Nucleic Acids Research, 2015, 43, 1759-1769.	6.5	15
82	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	1.9	15
83	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. Journal of Cellular Biochemistry, 2001, 83, 473-483.	1.2	14
84	Design and synthesis of a new dimeric xanthone derivative: enhancement of G-quadruplex selectivity and telomere damage. Organic and Biomolecular Chemistry, 2014, 12, 9572-9582.	1.5	14
85	Dyads of Gâ€Quadruplex Ligands Triggering DNA Damage Response and Tumour Cell Growth Inhibition at Subnanomolar Concentration. Chemistry - A European Journal, 2019, 25, 11085-11097.	1.7	14
86	Exploring the Interaction between the SWI/SNF Chromatin Remodeling Complex and the Zinc Finger Factor CTCF. International Journal of Molecular Sciences, 2020, 21, 8950.	1.8	14
87	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 111.	3.5	14
88	$\hat{l}^3$ -Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells. Molecular Pharmacology, 2007, 72, 1015-1023.	1.0	13
89	BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells. Genes, 2019, 10, 697.	1.0	13
90	Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia, 2004, 6, 195-206.	2.3	13

#	Article	IF	CITATIONS
91	Antiâ€tumoural activity of the Gâ€quadruplex ligand pyridostatin against BRCA1/2â€deficient tumours. EMBO Molecular Medicine, 2022, 14, e14501.	3.3	13
92	Identification of Effective Anticancer G-Quadruplex-Targeting Chemotypes through the Exploration of a High Diversity Library of Natural Compounds. Pharmaceutics, 2021, 13, 1611.	2.0	12
93	Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. Journal of Translational Medicine, 2011, 9, 125.	1.8	11
94	Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells. Journal of Thoracic Oncology, 2011, 6, 583-591.	0.5	10
95	TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer. Cancer Letters, 2022, 533, 215607.	3.2	9
96	A novel pathway links telomeres to NK-cell activity. Oncolmmunology, 2014, 3, e27358.	2.1	8
97	Anacardic acid and thyroid hormone enhance cardiomyocytes production from undifferentiated mouse ES cells along functionally distinct pathways. Endocrine, 2016, 53, 681-688.	1.1	7
98	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. British Journal of Cancer, 2003, 89, 1091-1095.	2.9	5
99	Synthesis and Characterization of Bis-Triazolyl-Pyridine Derivatives as Noncanonical DNA-Interacting Compounds. International Journal of Molecular Sciences, 2021, 22, 11959.	1.8	5
100	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 1830.	1.7	2
101	Evidence for G-quadruplex in the promoter of ÂVEGFR-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 14083-14083.	6.5	0
102	Abstract 266: The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models. , 2016, , .		0